Evotec’s (EVO) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Evotec (NASDAQ:EVO) in a research report report published on Thursday morning, Benzinga reports. HC Wainwright currently has a $11.00 target price on the stock.

Separately, Deutsche Bank Aktiengesellschaft raised shares of Evotec from a hold rating to a buy rating in a research report on Friday, April 12th.

Evotec Stock Down 3.2 %

EVO stock opened at $4.77 on Thursday. The firm has a 50 day moving average price of $6.42 and a 200-day moving average price of $8.10. Evotec has a 52-week low of $4.77 and a 52-week high of $13.49. The company has a current ratio of 1.86, a quick ratio of 2.09 and a debt-to-equity ratio of 0.43.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Mubadala Investment Co PJSC purchased a new position in shares of Evotec during the 4th quarter valued at $53,931,000. Optiver Holding B.V. lifted its stake in shares of Evotec by 643.1% during the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after buying an additional 69,936 shares in the last quarter. Cetera Advisors LLC purchased a new position in shares of Evotec during the 1st quarter valued at $188,000. Finally, Quadrant Capital Group LLC purchased a new position in shares of Evotec during the 4th quarter valued at $25,000. Hedge funds and other institutional investors own 5.81% of the company’s stock.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.